Aditya Bio - Speciality Medicines Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 14 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.50 Cr
About Aditya Bio - Speciality Medicines
Aditya Bio - Speciality Medicines Private Limited (ABSMPL) is a Private Limited Indian Non-Government Company incorporated in India on 04 May 2010 and has a history of 14 years and eight months. Its registered office is in Ahmedabad, Gujarat, India.
The Company is engaged in the Service Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.50 Cr.
Sanjay Parikh, Hitendra Patel, Sima Parikh, and One other member serve as directors at the Company.
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U24230GJ2010PTC060544
- Company No.
060544
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 May 2010
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Aditya Bio - Speciality Medicines?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjay Parikh  | Director | 04-May-2010 | Current |
| Hitendra Patel | Director | 04-May-2010 | Current |
| Sima Parikh | Director | 17-Dec-2013 | Current |
| Gargiben Patel | Director | 17-Dec-2013 | Current |
Financial Performance of Aditya Bio - Speciality Medicines.
Aditya Bio - Speciality Medicines Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Aditya Bio - Speciality Medicines?
In 2017, Aditya Bio - Speciality Medicines had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹15.00 M
₹0
Charges Breakdown by Lending Institutions
- The Mehsana Nagarik Sahakari Bank Limited : 1.50 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 07 Aug 2013 | The Mehsana Nagarik Sahakari Bank Limited | ₹1.50 Cr | Open |
How Many Employees Work at Aditya Bio - Speciality Medicines?
Unlock and access historical data on people associated with Aditya Bio - Speciality Medicines, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aditya Bio - Speciality Medicines, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aditya Bio - Speciality Medicines's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
